We previously reported a naturally occurring BF intersubtype recombinant viral protein U (Vpu) variant with an augmented capacity to enhance viral replication. Structural analysis of this variant revealed that its transmembrane domain and a-helix I in the cytoplasmic domain (CTD) corresponded to subtype B, whereas the a-helix II in the CTD corresponded to subtype F1. In this study, we aimed to evaluate the role of the Vpu cytoplasmic a-helix II domain in viral release enhancement and in the down-modulation of BST-2 and CD4 from the cell surface. In addition, as serine residues in Vpu amino acid positions 61 or 64 have been shown to regulate Vpu intracellular half-life, which in turn could influence the magnitude of viral release, we also studied the impact of these residues on the VpuBF functions, since S61 and S64 are infrequently found among BF recombinant Vpu variants. Our results showed that the exchange of Vpu a-helix II between subtypes (BAF) directly correlated with the enhancement of viral release and, to a lesser extent, with changes in the capacity of the resulting chimera to down-modulate BST-2 and CD4. No differences in viral release and BST-2 down-modulation were observed between VpuBF and VpuBF-E61S. On the other hand, VpuBF-A64S showed a slightly reduced capacity to enhance viral production, but was modestly more efficient than VpuBF in down-modulating BST-2. In summary, our observations clearly indicate that a-helix II is actively involved in Vpu viral-releasepromoting activity and that intersubtype recombination between subtypes B and F1 created a protein variant with a higher potential to boost the spread of the recombinant strain that harbours it.
INTRODUCTION
The viral protein U (Vpu), encoded in the human immunodeficiency virus (HIV)-1 genome (Cohen et al., 1988; Strebel et al., 1988) , is a type I transmembrane protein consisting of a short N-terminal domain, a single transmembrane a-helix domain, two cytosolic a-helices separated by a flexible connector loop, and a short Cterminal tail. This protein is known to perform two important functions during HIV-1 infection of target cells: (i) it mediates the proteasomal degradation of newly synthesized CD4 receptors in the endoplasmic reticulum (Magadán et al., 2010; Margottin et al., 1998) and (ii) it enhances viral release from infected cells by antagonizing the restriction imposed by BST-2 (CD317/HM1.24/ tetherin), an interferon-a-inducible host restriction factor (Neil et al., 2008; Van Damme et al., 2008) . In addition, it has been recently demonstrated that SLAMF6/NTB-A, a transmembrane protein that induces natural-killer-cellmediated killing of infected cells, is also downregulated from the plasma membrane by Vpu (Shah et al., 2010 ).
Early reports suggested that different Vpu domains were directing separate functions, identifying its cytoplasmic domain (CTD) as critical for CD4 degradation, and the transmembrane domain (TMD) as involved in the promotion of viral release (Schubert et al., 1994 (Schubert et al., , 1996a ; however, recent studies demonstrated that discrete regions in both the CTD and TMD are required to carry out its main functions (Mangeat et al., 2009; Magadán et al., 2010; Nomaguchi et al., 2010; Petit et al., 2011) .
We recently reported a naturally occurring BF intersubtype recombinant Vpu with an improved in vitro capacity to enhance viral replication when compared with a subtype B variant. The analysis of numerous BF intersubtype recombinant Vpu sequences revealed a highly conserved recombination pattern, similar to that observed in the prototypic BF recombinant strain CRF12_BF, in which the membrane-spanning and a-helix I domains correspond to subtype B, and the a-helix II to subtype F1 (De Candia et al., 2010) . This pattern displays a breakpoint in a flexible and highly conserved amino acid sequence located between a-helix I and II. This region contains two critical serine residues (S52 and S56), of which the phosphorylation by casein kinase II is crucial for proteasome-mediated CD4 degradation (Magadán et al., 2010; Margottin et al., 1998) and for the control of BST-2 intracellular trafficking and/or degradation (Douglas et al., 2009; Goffinet et al., 2009 Goffinet et al., , 2010 Mangeat et al., 2009; Mitchell et al., 2009; Miyagi et al., 2009; Schmidt et al., 2011; Tervo et al., 2011) .
On the other hand, according to an earlier report by Estrabaud et al. (2007) , Vpu degradation is a proteasomemediated process that involves phosphorylation of a serine residue at position 61 or 64 (S61 or S64) that triggers Vpu degradation by a b-TrCP-independent pathway that is not well elucidated. Replacement of S61 with alanine correlated with a marked increase in the protein half-life and, consequently, with the enhancement of viral release. This mutation did not affect CD4 degradation (Estrabaud et al., 2007; Hill et al., 2010) . We found that S61 is absent in the CRF12_BF Vpu sequence and in most of the related BF recombinant sequences, and that only 6.6 % of them have a serine residue at position 64 (De Candia et al., 2010) .
Taking all these data into account, the present work aimed to evaluate the contribution of a-helix II in the Vpu CTD, and assess the impact of serine residues at position 61 or 64 on the promotion of viral release and the capacity to downmodulate BST-2 and CD4 in order to clarify the relationship between the structural and functional variations observed in the BF recombinant Vpu.
RESULTS
BF Vpu's a-helix II results in an increase in viral release in Vpu-dependent cell line models
To evaluate the role of a-helix II in viral release and to assess the potential consequences of recombination involving this domain on Vpu functions, two different recombinant Vpu variants were generated: (i) VpuBF/B, where a-helix II from a CRF12_BF-like variant was replaced with the a-helix II from the NL4-3 reference strain, and (ii) VpuB/F1, where ahelix II from NL4-3 was replaced with the a-helix II from the CRF12_BF-like variant (Fig. 1a, b) . To evaluate the protein expression levels, the cloning strategy used included the incorporation of a 66His-tag at the C terminus of each recombinant protein variant. SDS-PAGE and Western blot analysis, as described in Methods, showed that all Vpu variants were expressed at similar levels (Fig. 2) . These proteins were fully functional, regarding the Vpu canonical activities.
HeLa cells were used as a Vpu-dependent model to evaluate viral production. As described in Methods, pNL4-3 U35 and each of the Vpu expression vectors pCG-VpuB, pCG-VpuF1, pCG-VpuBF, pCG-VpuB/F1 and pCG-VpuBF/B were used to separately co-transfect HeLa cell cultures. Co-transfection with the empty pCG vector was performed as a negative control. At 48 h posttransfection, viral production was monitored by quantifying p24 antigen in cell culture supernatants. Similar transfection efficiencies were achieved in all cases, as determined by the percentage of GFP-positive cells evaluated by FACS (data not shown).
As depicted in Fig. 3(a) , transfection with the VpuBF expression vector resulted in an approximately twofold increase in p24 production when compared with that of the VpuB, which is in line with our previous observations (De Candia et al., 2010) . Interestingly, VpuB/F1 was more efficient in promoting viral release than both VpuB and VpuF1 (P.0.01). Of note, viral production measured for VpuBF/B was lower than that associated with the naturally occurring VpuBF (P.0.01), resembling the VpuB biological behaviour. In this regard, no statistical differences were observed in p24 production among VpuBF/B versus VpuB or VpuBF versus VpuB/F1. VpuF1 p24 production was slightly but significantly higher than that of VpuB (P,0.01) and significantly lower than that of VpuBF (P,0.01).
These results clearly point out that in our intersubtype recombination study model, Vpu a-helix II is involved in the viral-release promoting function of Vpu.
A64S mutation in BF intersubtype recombinant Vpu affects viral release
Phosphorylation of serine residues by a protein kinase is a process known to induce functional changes in a target protein or to regulate a protein's fate (Cieśla et al., 2011; Johnson & Barford, 1993; Tarrant & Cole, 2009 ). As stated above, phosphorylation of serine residues at positions 52 and 56 (S52, S56) in the HIV-1 Vpu protein regulates its BST-2-and CD4-down-modulating capacity, while phosphorylation of serine residues at positions 61 or 64 (S61 or S64) has been found to influence the protein half-life (Estrabaud et al., 2007) . As shown in Fig. 1(a) , reference strain NL4-3 Vpu has a serine residue at position 61 (S61) and a valine residue at position 64 (V64), while BF intersubtype recombinant Vpu has a glutamic residue at position 61 (E61) and an alanine residue at position 64 (A64).
To test the hypothesis that the absence of S61 and/or S64 in the BF recombinant Vpu could contribute to an increase in the capacity to promote viral production, mutant Vpu variants, in which amino acids at positions 61 or 64 were replaced with serine residues (pCG-VpuBF E61S and pCGVpuBF A64S) (Fig. 1a) , were generated. VpuB expression vectors in which S61A and V64S mutations were introduced (pCG-VpuB S61A and pCG-VpuB V64S, respectively) were included as controls in the study.
The impact of these changes on p24 production was evaluated by performing HeLa cell co-transfections and p24 quantification as described above. We evaluated the protein expression level of each construct by Western blot analysis (Fig. 2) . No significant differences in p24 production were observed among VpuBF or VpuBF E61S. However, VpuBF A64S viral production was slightly but significantly lower than that for VpuBF (P,0.01; Fig. 3b ).
Different results were obtained for VpuB; in line with those reported by Estrabaud et al. (2007) , the replacement of S61 with alanine (VpuB S61A) was associated with a significant increase in p24 production when compared with that for the wild-type protein (VpuB), confirming that S61 contributes to the viral-enhancement function of this particular viral strain (NL4-3). When S61 was absent and the valine residue at position 64 was replaced with a serine residue (VpuB V64S), no significant difference in p24 production was observed.
Pure subtype, chimeric and serine-mutant Vpu variants have different capacities in downmodulating BST-2
To determine the relative capacity of pure subtype, chimeric and serine-mutant Vpu variants to downmodulate BST-2 from the cell surface, HeLa cell cultures were transfected with each Vpu-GFP expression vector as described above. Transfection with the empty vector pCG-GFP was performed as a negative control. Transfection efficiency, assessed as the percentage of GFP-positive cells, was similar in all cases (data not shown).
At 48 h post-transfection, BST-2 cell-surface expression was assessed by FACS and expressed as the mean fluorescence intensity (MFI) (Fig. 4) .
All the variants studied retained their capacity to downmodulate BST-2 from the cell surface. As shown in Fig.  4 (a), VpuBF was more efficient in modulating BST-2 when compared with VpuB and VpuF1 (P,0.01). Among the variants studied, VpuF1 was clearly the least efficient in down-modulating BST-2. No significant differences were observed when comparing the down-modulation by VpuBF with that by VpuB/F1 or VpuB with VpuBF/B. Remarkably, VpuBF and VpuB/F1 variants were more efficient in modulating BST-2 than VpuBF/B and VpuB, respectively, indicating that a-helix II is also implicated in Vpu-dependent BST-2 cell-surface down-modulation. Nevertheless, viral release and BTS-2 cell-surface expression observed for the BF recombinant variants did not show any direct correlation.
As for the role of serine residues in BST-2 expression (Fig. 4b) , no statistically significant differences were observed between VpuB and VpuB S61A or VpuBF and VpuBF E61S. Interestingly, VpuBF A64S showed a slightly lower capacity in down-modulating BST-2 from the cell surface than VpuBF (P,0.01).
Pure subtype and chimeric Vpu have different capacities to down-modulate CD4 expression
We subsequently examined and compared the ability of pure subtype, chimeric and serine-mutant Vpu variants to induce the down-modulation of CD4 from the cell surface.
HeLa T4 cells were transfected separately with each Vpu-GFP expression vector. Transfection with the empty vector pCG-GFP was performed as a negative control.
At 48 h post-transfection, CD4 cell-surface expression in Vpu-expressing cells was evaluated by FACS, and expressed as the MFI. Similar transfection efficiencies, determined as the percentage of GFP-positive cells by FACS, were obtained in all cases (data not shown).
All Vpu variants efficiently reduced CD4 cell-surface expression when compared with the result with the empty vector (Fig. 5 ). As shown in Fig. 5(a) , VpuF1, VpuBF and VpuB/F1 were more efficient in down-modulating CD4 from the cell surface than VpuB (P,0.01). No statistically significant differences were observed between VpuBF and VpuB/F1 or between VpuB and VpuBF/B.
Regarding the effect of the serine residues at positions 61 and 64 on CD4 cell-surface expression, no statistically significant differences were observed between the serinemutant Vpu variants studied (Fig. 5b) . It has been proposed that the fact that only HIV-1 strains from the M group express a fully functional Vpu protein may explain, at least in part, the global HIV/acquired immunodeficiency syndrome pandemic for the HIV-1 M group Sauter et al., 2009 Sauter et al., , 2011 . Notably, among the 51 circulating recombinant forms described up to now, just four of them exhibit a recombinant structure involving the Vpu-coding sequence; of them, CRF02_AG and CRF12_BF are the most-represented recombinant forms in the infected population (Hemelaar et al., 2011) . This might reflect some as-of-yet unclear recombination restrictions at this region and the importance of the conservation/preservation of its function.
DISCUSSION
In a previous study we found that a naturally occurring BF intersubtype recombinant Vpu has an improved in vitro capacity to enhance viral replication. In addition, it was observed that the recombination pattern of other numerous BF recombinant sequences is very similar to that observed in CRF12_BF, first described in Argentina. In a comparative analysis between subtype B and intersubtype BF recombinant Vpu amino acid sequences, major differences were found in the a-helix II and C-terminal domains. This protein region has been strongly associated with Vpu functions; therefore, partial and full deletions of the CTD negatively affected its capacity to down-modulate CD4 (Pacyniak et al., 2005) or to promote viral release (Dubé et al., 2009 ). Taking this data into account, the aim of this work was to determine the relevance of a-helix II on the functional changes observed for the BF recombinant Vpu. To achieve this, two chimeric proteins, in which the a-helix II domains were exchanged between NL4-3 and BF recombinant variants, were generated and used in in vitro studies.
Our results indicate that the replacement of a-helix II (BAF), resembling the structure of the naturally occurring recombinant variant, directly correlated with the enhancement of viral release and with a moderate increase in the ability to down-modulate BST-2 and CD4. This observation shows that the a-helix II participates actively in the viral-release-promoting activity of Vpu.
We also found that subtype F1 Vpu was relatively less efficient in reducing BST-2 cell-surface expression levels than the subtype B and intersubtype BF recombinant Vpu studied. Nevertheless, its capacity to promote viral release was slightly higher than that observed for the subtype B variant.
Of note, the relative augmentation of viral production among the variants studied did not directly correlate with their capacity to down-modulate BST-2 from the cell surface. This discrepancy has been observed in many studies (Dubé et al., 2010; Goffinet et al., 2010; Kuhl et al., 2011; Mitchell et al., 2009; Miyagi et al., 2009; Nomaguchi et al., 2010) , which leads to the hypothesis that both activities may be relatively independent. In this regard, Schmidt et al. (2011) found that Vpu may interfere with both the BST-2 recycling from the cell surface and the anterograde transport of newly synthesized BST-2, without affecting its internalization rate, which leads to a reduction in its virion-tethering activity at the cell surface. Thus, BST-2 intracellular subpopulations with different trafficking characteristics and/or susceptibility to Vpu may exist and may have a higher antiviral activity potential than molecules at the cell surface, explaining the lack of a precise correlation among viral production and BST-2 cell-surface expression.
On the other hand, the motif (E/D)XXXL(V/M/I) within a-helix II, which is highly conserved among Vpu proteins from HIV-1 M group subtypes A, B, D, G and H, has been recently identified as necessary for efficient BST-2 downmodulation and the enhancement of viral release (Kueck & Neil, 2012) . Vpu variants used in this work displayed differences in the location and amino acid composition of this motif, i.e. E 59 XXXL 63 V in subtype B and (D/ E) 62 XXXL 66 (A) in subtype F1 and BF recombinant, and as suggested by Kueck & Neil (2012) , such motifs may not be functionally equivalent.
Proteasomal degradation of Vpu, which occurs through a b-TrCP-complex-independent pathway, has been shown to involve phosphorylation of a serine residue at position 61 (Estrabaud et al., 2007) . Mutation of S61 led to the accumulation of Vpu within cells and the augmentation of viral release. S61 is not present in CRF12_BF or related BF recombinant Vpu sequences, and only 6.6 % of BF HIV-1 BF intersubtype recombinant Vpu sequences had S64 (De Candia et al., 2010) . These results prompted us to examine the effect of S61 and S64 on the BF recombinant Vpu function. Our results showed that both VpuBF E61S and the wild-type VpuBF E61 variants behaved similarly in terms of promoting viral release in a tetherin-expressing cell model. Nevertheless, we found a modest reduction in viral production when the alanine residue at position 64 was replaced with serine. This change also correlated with a slight increase in the capacity of the VpuS64 variant to down-modulate BST-2. No changes in CD4 degradation were observed in VpuBF E61S or VpuBF A64S. Although the biological impact of these small differences remains to be established, these results suggest that the regulation of Vpu degradation and the relationship with protein functions are a complex process for which other steps may be required, regardless of the simple phosphorylation event.
In summary, data presented here clearly show that structural modifications introduced by the intersubtype recombination in BF Vpu at the level of its a-helix II correlates with the previously observed augmentation in viral production and with changes in its capacity to modulate the steady-state BST-2 and/or CD4 cell-surface levels. Regarding the role of residues S61 and S64 in the BF Vpu function, we found that S64, but not S61, affected the capacity of Vpu to down-modulate BST-2 and to promote viral release. To the best of our knowledge, this is the first report on a non-B subtype Vpu variant.
Altogether, these findings shed more light on the molecular basis of Vpu function, underscoring the power of recombination as a variability source during HIV-1 evolution.
In an elegant report by Sato et al. (2012) , it was shown that Vpu enhances the kinetics of cell-free virus propagation, especially during the initial phase of infection, which leads to a rapid systemic HIV-1 dissemination in vivo. Thus, if intersubtype recombination has the potential to generate structurally reorganized proteins with improved functions, such as the BF intersubtype recombinant Vpu, then viruses harbouring them may have biological advantages that play an important role in the successful spread of such HIV-1 recombinant variants.
METHODS
Plasmids. To perform the functional analysis, we generated vectors coexpressing Vpu and GFP from a single bicistronic RNA via an internal ribosome entry site. Briefly, vpu genes from HIV-1 subtype B molecular clone pNL4-3 (Adachi et al., 1986) , subtype F1 molecular clone p93BR020.1 (Gao et al., 1998 ) and pVpuBF vector previously described (De Candia et al., 2010) were used as templates for a PCR designed to introduce the XbaI restriction site and a C-terminus 66His tag/MluI restriction site at 59 and 39 ends of the vpu-coding sequence, respectively. Primers used for this reaction were: VpuB-XbaI (59-CCTCTAGATAATGCAACCTATAATAG-39), VpuB-66His-MluI (59-CACGCGTTTAGTGATGGTGATGATGATGGCCGGATCCCAGATC-ATCAATATCC-39), VpuF1-XbaI (59-CCTCTAGATAATGTCAAATT-TGTTAGC-39), VpuF1-66His-MluI (59-CACGCGTTTAGTGATGG-TGATGATGATGGCCGGATCCCAGATTATTAATGTCC-39), VpuBF
XbaI (59-CCTCTAGATAATGCAATCTTTAG-39) and VpuBF 66His-MluI (59-CACGCGTTTAGTGATGGTGATGATGATGGCCGGATCC-CAGAATATCAATATTC-39). Nucleotide changes corresponding to restriction sites and sequence coding for the 66His tag are underlined. The original Vpu stop codon was eliminated with the addition of the GSGHHHHHH amino acid sequence, and a new one was generated at the end of the tag (highlighted in bold). The amplicons obtained were first cloned into a commercial vector (pGEM-T Easy Vector; Promega) and then subcloned into the XbaI/MluI-harbouring bicistronic, cytomegalovirus-based pCG expression vector co-expressing GFP (Lock et al., 1999; Mariani & Skowronski, 1993) , generating expression vectors pCG-VpuB, pCG-VpuF1 and pCG-VpuBF. All mutagenesis reactions were performed using a highly processive DNA polymerase with proofreading 39-59 exonuclease activity (Platinum Pfx DNA Polymerase; Invitrogen). The Vpu expression vectors were then sequenced to assess vpu sequence integrity (Big Dye terminator kit and an ABI 3100 automated sequencer; Applied Biosystems). The nucleotide sequences from both stands were analysed and manually adjusted using Sequencher 4.0.5 software (Gene Codes).
For the construction of chimeric Vpu proteins, plasmids pCG-VpuB and pCG-VpuBF were digested with both XbaI and BpiI; digestion products (vector and insert containing coding sequences for the ahelix II and C-terminal domains) were gel purified and appropriate ligations were carried out using T4 DNA ligase (Promega). The resulting plasmids were named pCG-VpuBF/B, where a-helix II from CRF12_BF-like variant was replaced with that from NL4-3, and pCGVpuB/F1, where a-helix II from NL4-3 was replaced with that from the CRF12_BF-like variant (Fig. 1) .
Mutations of serine at position 61 or 64 in pCG-VpuBF, serine at position 64 in pCG-VpuB and alanine at position 61 in pCG-VpuB were introduced by site-directed mutagenesis. Briefly, PCR was carried out by using the following set of forward primers, where codon substitutions are underlined: VpuB S61A (59-GGAGAAGTAGCAGCACTTGTGG-39), VpuB V64S (59-GAAGTAGCAGCACTTTCGGAGATG-39), VpuBF E61S (59-GGATGCATCAGAATTGGCAGC-39) and VpuBF A64S (59-GGATGCAGAAGAATTGTCAGC-39). The amplicons were subcloned into a commercial vector (pGEM-T Easy Vector; Promega) and then subcloned into a pCG expression vector. The resulting vectors were sequenced to ensure that the mutation was introduced and to assess any possible unwanted changes introduced during mutagenesis. The resulting plasmids were named pCGVpuBF E61S, pCG-VpuBF A64S, pCG-VpuB S61A and pCG-VpuB V64S (Fig. 1 ).
pNL4-3 U35 (Strebel et al., 1988) , a derivative of pNL4-3, contains an insertion within the vpu ORF that causes a translational frameshift which results in a 35-aa truncated form of the Vpu protein; this was used as a negative control.
Cells. HeLa and HeLa CD4 + cells were used in this study. HeLa cells were cultured in Dulbecco's modified Eagle's medium (Gibco) supplemented with 10 % FBS (Gibco), 2 mM L-glutamine (Gibco) and penicillin/streptomycin (100 IU ml 21 and 100 mg ml 21 , respectively; Gibco). HeLa CD4 + cells were cultured in the same medium plus 500 mg ml 21 G418. Cell lines were obtained through the AIDS Research and Reference Reagent Program.
Viral release assay. HeLa cells were co-transfected with 2 mg HIV-1 proviral DNA (pNL4-3 U35) and 0.5 mg of each of the Vpu expression vectors. Co-transfection with 500 ng pCG-GFP empty vector was represented a negative control. Transient transfections were carried out using Lipofectamine2000 (Invitrogen), following the manufacturer's instructions. Cell culture supernatants were collected 24 and 48 h post-transfection. HIV-1 p24 antigen levels were measured using a commercial ELISA kit (Murex). HeLa CD4 + cells were stained with PE-conjugated anti-CD4 mAb (BD Bioscience) in 1 % BSA-PBS. Cells were washed twice with icecold 1 % BSA-PBS and were analysed as described above.
Western blotting. Vpu expression was assessed by transfecting HeLa cells with 4 mg of each pCG-Vpu expression vector using Lipofectamine2000 (Invitrogen), following the manufacturer's instructions. At 48 h post-transfection, cells were harvested and lysed in RIPA buffer (1 % NP-40, 0.5 % Na-DOC, 0.1 % SDS, 0.15 M NaCl; 50 mM Tris/HCl pH 7.4; 5 mM EDTA, protease inhibitor cocktail). Lysates were boiled at 95 uC for 5 min, separated on 12.5 % SDS-PAGE gels under reducing conditions. After gel electrophoresis, proteins were transferred onto PVDF membranes. The expression of each Vpu variant in whole cellular lysates was analysed by immunoblot using 1 : 2000 diluted mouse anti-66His (BD Pharmingen) and secondary peroxidase-labelled, sheep anti-mouse antibody (Amersham Biosciences) at 1 : 2000 for chemiluminescent detection (ECL; GE Healthcare). b-Actin was used as the loading control by immunoblot using 1 : 3000 diluted rabbit anti-b-actin (Abcam) and secondary peroxidase-labelled, goat anti-rabbit antibody (Abcam) at 1 : 2000 for chemiluminescent detection (ECL; GE Healthcare). Band intensity was quantified using ImageJ software.
Statistical analysis. ANOVA with Tukey's post test (one-way ANOVA for comparison between groups) was used. P,0.01 was considered statistically significant.
